These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 18271928)

  • 1. Expression of CCL17 and CCL22 by latent membrane protein 1-positive tumor cells in age-related Epstein-Barr virus-associated B-cell lymphoproliferative disorder.
    Takegawa S; Jin Z; Nakayama T; Oyama T; Hieshima K; Nagakubo D; Shirakawa AK; Tsuzuki T; Nakamura S; Yoshie O
    Cancer Sci; 2008 Feb; 99(2):296-302. PubMed ID: 18271928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective induction of Th2-attracting chemokines CCL17 and CCL22 in human B cells by latent membrane protein 1 of Epstein-Barr virus.
    Nakayama T; Hieshima K; Nagakubo D; Sato E; Nakayama M; Kawa K; Yoshie O
    J Virol; 2004 Feb; 78(4):1665-74. PubMed ID: 14747532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EBV+ tumors exploit tumor cell-intrinsic and -extrinsic mechanisms to produce regulatory T cell-recruiting chemokines CCL17 and CCL22.
    Jorapur A; Marshall LA; Jacobson S; Xu M; Marubayashi S; Zibinsky M; Hu DX; Robles O; Jackson JJ; Baloche V; Busson P; Wustrow D; Brockstedt DG; Talay O; Kassner PD; Cutler G
    PLoS Pathog; 2022 Jan; 18(1):e1010200. PubMed ID: 35025968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epstein-Barr virus-positive pyothorax-associated lymphoma expresses CCL17 and CCL22 chemokines that attract CCR4-expressing regulatory T cells.
    Higuchi T; Matsuo K; Hashida Y; Kitahata K; Ujihara T; Taniguchi A; Yoshie O; Nakayama T; Daibata M
    Cancer Lett; 2019 Jul; 453():184-192. PubMed ID: 30953706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma.
    van den Berg A; Visser L; Poppema S
    Am J Pathol; 1999 Jun; 154(6):1685-91. PubMed ID: 10362793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients.
    Liebowitz D
    N Engl J Med; 1998 May; 338(20):1413-21. PubMed ID: 9580648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer.
    Mizukami Y; Kono K; Kawaguchi Y; Akaike H; Kamimura K; Sugai H; Fujii H
    Int J Cancer; 2008 May; 122(10):2286-93. PubMed ID: 18224687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CCL17 and CCL22 chemokines within tumor microenvironment are related to infiltration of regulatory T cells in esophageal squamous cell carcinoma.
    Maruyama T; Kono K; Izawa S; Mizukami Y; Kawaguchi Y; Mimura K; Watanabe M; Fujii H
    Dis Esophagus; 2010 Jul; 23(5):422-9. PubMed ID: 20002703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A20 (TNFAIP3) deletion in Epstein-Barr virus-associated lymphoproliferative disorders/lymphomas.
    Ando M; Sato Y; Takata K; Nomoto J; Nakamura S; Ohshima K; Takeuchi T; Orita Y; Kobayashi Y; Yoshino T
    PLoS One; 2013; 8(2):e56741. PubMed ID: 23418597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Common and differential chemokine expression patterns in rs cells of NLP, EBV positive and negative classical Hodgkin lymphomas.
    Maggio EM; Van Den Berg A; Visser L; Diepstra A; Kluiver J; Emmens R; Poppema S
    Int J Cancer; 2002 Jun; 99(5):665-72. PubMed ID: 12115499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CCL17 acts as an antitumor chemokine in micromilieu-driven immune skewing.
    Li Y; Cao H; Jiang Z; Yan K; Shi J; Wang S; Wang F; Wang W; Li X; Sun N; Liu L; Chen L; Chen Y; Guo R; Song Y
    Int Immunopharmacol; 2023 May; 118():110078. PubMed ID: 37001380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epstein-Barr virus latency patterns in polymorphic lymphoproliferative disorders and lymphomas in immunodeficiency settings: Diagnostic implications.
    Volaric AK; Saleem A; Younes SF; Zhao S; Natkunam Y
    Ann Diagn Pathol; 2024 Jun; 70():152286. PubMed ID: 38447253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of age-related Epstein-Barr virus (EBV)-associated B cell lymphoproliferative disorder, so-called polymorphous subtype, of the mandible, with a review of the literature.
    Kikuchi K; Fukunaga S; Inoue H; Miyazaki Y; Kojima M; Ide F; Kusama K
    Head Neck Pathol; 2013 Jun; 7(2):178-87. PubMed ID: 22869357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced PD-L1 Expression in LMP1-positive Cells of Epstein-Barr Virus-associated Malignant Lymphomas and Lymphoproliferative Disorders: A Single-cell Resolution Analysis With Multiplex Fluorescence Immunohistochemistry and In Situ Hybridization.
    Kume A; Shinozaki-Ushiku A; Kunita A; Kondo A; Ushiku T
    Am J Surg Pathol; 2022 Oct; 46(10):1386-1396. PubMed ID: 35605962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr Virus-Encoded Latent Membrane Protein 1 and B-Cell Growth Transformation Induce Lipogenesis through Fatty Acid Synthase.
    Hulse M; Johnson SM; Boyle S; Caruso LB; Tempera I
    J Virol; 2021 Jan; 95(4):. PubMed ID: 33208446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasmacytic hyperplasia in age-related Epstein-Barr virus-associated lymphoproliferative disorders: a report of two cases.
    Kojima M; Morita Y; Nakamura N; Shimizu K; Murayama K; Nakamura S
    Pathol Res Pract; 2008; 204(4):267-72. PubMed ID: 18187262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent expression of the tumor necrosis factor receptor-associated factor 1 in latent membrane protein 1-positive posttransplant lymphoproliferative disease and HIV-associated lymphomas.
    Murray PG; Swinnen LJ; Flavell JR; Ragni MV; Baumforth KR; Toomey SM; Filipovich AH; Lowe D; Schnell CS; Johl J; Gulley M; Young LS; Ambinder RF
    Hum Pathol; 2001 Sep; 32(9):963-9. PubMed ID: 11567226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma.
    Kumai T; Nagato T; Kobayashi H; Komabayashi Y; Ueda S; Kishibe K; Ohkuri T; Takahara M; Celis E; Harabuchi Y
    Cancer Immunol Immunother; 2015 Jun; 64(6):697-705. PubMed ID: 25754123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCL17 and CCL22 induce CCR4 receptor expression and promote cytokine-induced killer cells migration.
    Dong Y; Gao S; Zhang X; Kou J; Liu J; Ye T; Shen H
    Anticancer Drugs; 2022 Feb; 33(2):149-157. PubMed ID: 34657098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the CCL17/CCL22-CCR4 axis in pediatrics with B-cell acute lymphoblastic leukemia before and after a chemotherapy course.
    Motaghi M; Jafarzadeh A; Farsinejad A; Norouzi A; Khorramdelazad H; Farahmandinia Z; Afgar A; Hassanshahia G
    Cytokine; 2024 Oct; 182():156721. PubMed ID: 39106576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.